---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-26-000010"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:12:06.721770+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma sues Torrent, Somerset over Recorlev patent infringement

## Summary
- Filed Hatch-Waxman lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics over ANDA for generic Recorlev.
- Lawsuit alleges infringement of four Orange Book patents expiring March 2040 (U.S. Patent Nos. 11,020,393, 11,278,547, 11,903,940, 12,377,096).
- Seeks injunction to block generic competition until patent expiry in March 2040.
- Recorlev also benefits from Orphan Drug Exclusivity through December 2028.
- CEO John P. Shannon cites confidence in IP and intention to vigorously defend.

## SEC filing metadata
- accession: 0001867096-26-000010
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000010/0001867096-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000010/xers-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-26-000010
- JSON: https://secwatch.observer/filing/0001867096-26-000010.json
- Plain text: https://secwatch.observer/filing/0001867096-26-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.